Remynd NV raised €3.5 million from the Alzheimer’s Drug Discovery Foundation to advance REM-392, an orally available septin-targeting small molecule. The company said the additional funding addresses prior liver toxicity issues and supports a Phase Ib study expected to begin in early 2027 in mild to moderate Alzheimer’s disease. The financing illustrates how Alzheimer’s drug developers are prioritizing candidates with workable safety packages and clear mechanistic differentiation amid a crowded landscape. For biotech observers, Remynd’s restart also highlights how targeted preclinical toxicology fixes can be a gating item for regaining clinical momentum.